There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aptose Biosciences (APTO – Research Report) and Frequency Therapeutics (FREQ – Research Report) with bullish sentiments.
Aptose Biosciences (APTO)
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aptose Biosciences today and set a price target of $8.00. The company’s shares closed last Tuesday at $1.28, close to its 52-week low of $1.00.
According to TipRanks.com, Roy is a 4-star analyst with an average return of
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $9.00, which is a 625.8% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
Frequency Therapeutics (FREQ)
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Frequency Therapeutics today and set a price target of $10.00. The company’s shares closed last Tuesday at $2.49, close to its 52-week low of $1.62.
According to TipRanks.com, Mamtani is ranked 0 out of 5 stars with an average return of
Frequency Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APTO: